The Lancet Respiratory Medicine: Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia

(The Lancet) Chronic obstructive pulmonary disease is associated with eosinophilic airway inflammation in 10-20 percent of patients. Benralizumab, a monoclonal antibody, has been shown to decrease the number of blood and sputum eosinophils.